Department of General Surgery, Breast Cancer Unit, Complexo Hospitalario de Ourense, Calle Ramon Puga Noguerol, 54, 32005, Ourense, Spain.
Hospital Público de Verín, Ourense, Spain.
J Robot Surg. 2023 Dec;17(6):2583-2596. doi: 10.1007/s11701-023-01698-5. Epub 2023 Aug 25.
Robotic-assisted breast surgery (RABS) is controversial. We systematically reviewed the evidence about RABS, comparing it to open conventional breast surgery (CBS). Following prospective registration (osf.io/97ewt), a search was performed in January 2023, without time or language restrictions, through bibliographic databases (PubMed, Web of Science, EMBASE, Scopus, Trip database and CDSR) and grey literature. Quality was assessed in duplicate using Qualsyst criteria (score range 0.0-1.0); reviewer agreement was 98%. The 16 selected studies (total patients: 334,804) had overall high quality (mean score 0.82; range 0.68-0.91). Nine of 16 (56.3%) were cohort studies, 2/16 (12.5%) RCTs, and 5/16 (31.3%) case-control studies. Taking p < 0.05 as the significance threshold, RABS versus CBS was better in aesthetic results and patient satisfaction (10/11 studies; 90%), was surgically costly (4/4 studies; 100%), time-consuming (9/13 studies; 69%), and less painful in the first 6-24 h (2/2 studies; 100%) and without statistically significant differences in complication rates (10/12 studies; 83%) or short-term oncological outcomes (10/10 studies; 100%). Surgical time could be dramatically reduced by training surgical teams, reaching no significant differences between approaches (p = 0.120). RABS was shown to be feasible and safe. The advantages of RABS and long-term outcomes need further research.
机器人辅助乳房手术(RABS)存在争议。我们系统地回顾了 RABS 的证据,将其与开放式常规乳房手术(CBS)进行比较。在前瞻性注册(osf.io/97ewt)后,于 2023 年 1 月进行了无时间和语言限制的检索,通过文献数据库(PubMed、Web of Science、EMBASE、Scopus、Trip 数据库和 CDSR)和灰色文献进行检索。使用 Qualsyst 标准(评分范围 0.0-1.0)进行重复评估质量;审稿人之间的一致性为 98%。16 项入选研究(总患者数:334804 人)整体质量较高(平均评分为 0.82;范围为 0.68-0.91)。其中 9 项为队列研究(56.3%),2 项为 RCT(12.5%),5 项为病例对照研究(31.3%)。以 p<0.05 为显著性阈值,RABS 与 CBS 在美容效果和患者满意度方面更好(11 项研究中的 10 项;90%),手术成本更高(4 项研究中的 4 项;100%),耗时更长(13 项研究中的 9 项;69%),在术后 6-24 小时内疼痛程度更低(2 项研究中的 2 项;100%),并发症发生率无统计学差异(12 项研究中的 10 项;83%)或短期肿瘤学结果(10 项研究中的 10 项;100%)。通过对手术团队进行培训,可以显著缩短手术时间,两种方法之间无显著差异(p=0.120)。RABS 被证明是可行且安全的。RABS 的优势和长期结果需要进一步研究。